Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Why a signalling pathway activated by AMP?
- Phosphotransfer relays: creatine and AMP
- Regulation of AMPK by AMP and ATP
- Function of AMPK orthologues in lower eukaryotes
- AMPK as a drug target in type 2 diabetes
- Regulation of metabolism by AMPK activation
- Regulation of AMPK by drugs, cytokines and more
- Anti-diabetic drugs: phenformin and metformin
- Phytochemicals from foods, beverages and more
- Identification of upstream kinases
- AMPK regulation - upstream kinases
- The budding yeast kinome (1)
- Activation of AMPK by yeast kinases
- The budding yeast kinome (2)
- The human kinome
- LKB1 - a tumour suppressor
- More upstream kinase - CaMKKs
- Upstream kinases acting on AMPK
- Identification of AMP-binding sites
- Domain structure of AMPK
- Mutations in gamma-2 CBS cause heart disease
- Gamma-2 mutations reduce AMP and ATP binding
- Mutated residues are involved in AMP binding (1)
- Mutated residues are involved in AMP binding (2)
- AMPK as a drug target in cancer
- AMPK activators: potential anti-cancer drugs
- AMPK activators protect PTEN+/- LKB1fl/fl mice
- AMPK activation is reduced in breast tumours
- AMP-activated protein kinase - conclusions
- Acknowledgements
Topics Covered
- AMPK-activated protein kinase
- Role as a cellular energy sensor
- Role in lower eukaryotes
- Metabolic pathways targeted by AMPK
- Cytokines, drugs (including metformin) and xenobiotics that target AMPK
- Identification of upstream kinases
- Regulation by AMP, ATP and calcium ions
- Potential of AMPK as a drug target in cancer
Talk Citation
Hardie, G. (2010, November 30). AMP-activated protein kinase: regulating cellular and whole body energy balance [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/URHA6472.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Grahame Hardie has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
AMP-activated protein kinase: regulating cellular and whole body energy balance
A selection of talks on Biochemistry
Hide